Financial Analyst
- Employer
- Molecular Templates, Inc.
- Location
- Austin, TX, USA
- Start date
- Apr 10, 2021
View more
- Discipline
- Administration, Finance
- Required Education
- Other
- Position Type
- Full time
- Hotbed
- Lone Star Bio
Job Details
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated, targeted, biologic therapeutics.
Our proprietary biologic drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases. MTEM currently has multiple clinical-stage ETB candidates in development including MT-5111, TAK-169, and MT-6402. Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development.
Additional information about Molecular Templates can be obtained at www.mtem.com.
Position Overview:
Molecular Templates is seeking a highly skilled and highly motivated Financial Analyst who will be the primary point of contact between Operational Business Groups, Project Management and Finance/Accounting. This position is responsible for all financial aspects of assigned projects, including review of project plans, internal monthly reporting, and analysis, updating all areas of OPEX and CAPEX planning, including headcount. This position will assist with preparation of presentations for all levels of the business from department to Board of Directors.
Job Responsibilities:
- Provide accurate and timely financial analyses to support our operational department managers, project managers, financial project management department, and external auditors
- Work together with area leaders to update budget/forecast information into Planful (formerly Host Analytics), maintaining accurate information within the system.
- Review/analyze assigned projects at least monthly
- Develop accruals as needed
- Develop and maintain Milestone Payment Schedule
- Attend Project Review meetings to ensure understanding of project status, potential issues and to support the project manager with project finance questions
- Prepare/Review monthly and ad hoc reporting
- Assist with quarterly and year-end financial audits as well as ad-hoc requests
- May act as Finance-based administrator for applications such as R&D Logic, Planful, etc.
- Other project financial analysis duties as required
Qualifications:
- Bachelor's in Finance/Accounting/Business Systems or related business field of study
- 1 to 3+ years of progressive experience in financial analysis, planning and budgeting is required
- Strong MS Office skills, especially Excel Pivot tables, sumif, lookups, index/match, etc.
- Basic knowledge of accounting applying US GAAP
- Exceptional attention to detail, accuracy, organizational, interpersonal, and teamwork skills
- Ability to manage several tasks simultaneously to meet deadlines as necessary
- Strong organizational, analytical, and problem-solving skills
Preferred Qualifications:
- Biopharma or Healthcare industry experience, including internships
- MBA, CMA or CPA (completed or in process)
- Knowledge of Business Intelligence applications
Reporting Structure:
This position currently has no supervisory responsibilities. This position reports to the Director, Financial Planning and Analysis.
Molecular Templates, Inc. is an Equal Opportunity Employer and offers competitive salaries and benefits.
Molecular Templates Inc https://mtem.isolvedhire.com
Company
Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, which is in a Phase I clinical trial to treat relapsed/refractory myeloma. Additional preclinical compounds derived from our ETB platform technology are being advanced toward clinical development. Additional information about MTEM can be obtained at www.mtem.com.
OWNERSHIP: Public
STOCK SYMBOL: MTEM
STOCK EXCHANGE: NASDAQ
- Website
- http://mtem.com/
- Phone
- 512-869-1555
- Location
-
9301 Amberglen Blvd, Ste 100
Austin
TX
78729
US
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert